They see GLP-1 agonists and biologics like Humira pushing prices up at the highest rate since at least 2010.

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy or Zepbound. Nevertheless, since 2018, Optum Rx charged the union health plan $4,381,075 for 3,732 claims for uncovered weight-loss drugs, the plaintiffs alleged.

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential cost savings that is easily in the billions of dollars, the company said.